Figure 2.
dCLN lymphatics expand after tMCAO. (A–D) Sections of dCLNs (A) and peripheral lymph nodes such as axillary (B), inguinal (C), and popliteal (D) were immunolabeled with Lyve-1 fluorescent antibody after 7 days of sham and tMCAO. Representative confocal images of each lymph node with orange lines to define the areas of lymph nodes. Scale bars = 100 µm. Quantitation of percentage of Lyve-1+ vessel area over lymph node areas (n = 6 mice per group for cervical lymph nodes, n = 3 mice per group for axillary, inguinal, and popliteal lymph nodes; mean ± SEM, ****P ≤ 0.0001, unpaired Student’s t test). Source data are available for this figure: SourceData F2.

dCLN lymphatics expand after tMCAO. (A–D) Sections of dCLNs (A) and peripheral lymph nodes such as axillary (B), inguinal (C), and popliteal (D) were immunolabeled with Lyve-1 fluorescent antibody after 7 days of sham and tMCAO. Representative confocal images of each lymph node with orange lines to define the areas of lymph nodes. Scale bars = 100 µm. Quantitation of percentage of Lyve-1+ vessel area over lymph node areas (n = 6 mice per group for cervical lymph nodes, n = 3 mice per group for axillary, inguinal, and popliteal lymph nodes; mean ± SEM, ****P ≤ 0.0001, unpaired Student’s t test). Source data are available for this figure: SourceData F2.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal